Successfully merged with Immunovant • Now trading as IMVT
SPAC Overview
$100M
IPO Size
Completed
Current Status
2019
IPO Year
Timeline Progress
Investment Focus
Biopharma & medical technology in North America or Europe
SPAC Team
Leadership
Roderick Wong, MD
President and Chief Executive Officer and Chairman
Naveen Yalamanchi, MD
Executive Vice President, Chief Financial Officer and Director
Alice Lee, JD
Vice President of Operations, Secretary and Treasurer
Stephanie A. Sirota
Vice President of Corporate Strategy and Corporate Communications
Mark Schoenebaum, MD
Director
Sukumar Nagendran, MD
Director
Pedro Granadillo
Director
George Migausky
Director
Gotham Makker, MD
Director
Alice Lee, JD
Vice President of Operations, Secretary and Treasurer
Underwriters
Stock Performance
IMVT
Trading Symbol
First Trade
June 26, 2019
$9.80
At Merger
February 3, 2020
$15.97
+63%
6 Months Post-Merger
August 3, 2020
$23.39
+46%
1 Year Post-Merger
February 1, 2021
$43.30
+171%
2 Years Post-Merger
January 31, 2022
$6.99
-56%
Current Price
May 30, 2025
$14.87
+52%
Key Information
May 11, 2019
January 31, 2020
Immunovant
HSACU
IMVT